SGMC Health has successfully performed its first procedure using the Abiomed Impella 5.5 with SmartAssist, a minimally ...

Investigators randomly assigned patients with STEMI and cardiogenic shock to receive the Impella CP plus standard care or standard care alone. The primary endpoint was death from any cause at 180 ...

confirms routine use of Impella CP in patients who have had a heart attack with STEMI cardiogenic shock reduces 180-day mortality by 12.7%, compared to the control arm (45.8% vs. 58.5% ...

In an international, multicenter, randomized trial, we assigned patients with STEMI and cardiogenic shock to receive a microaxial flow pump (Impella CP) plus standard care or standard care alone.

The RECOVER IV randomized trial of the Impella (Abiomed) mechanical circulatory device in patients with STEMI complicated by cardiogenic shock has been halted, its two principal investigators have ...

The analysis examined 143 consecutive patients with cardiogenic shock due to myocarditis who received Impella support or Impella plus VA ECMO support, known as ECpella. These patients are included ...

The Impella heart pump is a small pump that a healthcare professional can insert without surgery. It can help maintain blood flow in people who have CAD, are recovering from cardiogenic shock ...

Impella is the only mechanical circulatory support device for the treatment of AMI cardiogenic shock with premarket approval from the United States Food and Drug Administration. Multiples studies ...

She also drew attention to the Impella trial that gave half of patients with MI-related cardiogenic shock a microaxial flow pump (Impella CP) in addition to standard of care. "This is another ...

The IABP, developed in the 1960s, was the first device to provide temporary mechanical support to the heart in patients with cardiogenic shock, Sacco said. Although other such devices have been ...

Get Instant Summarized Text (Gist) Early use of an intra-aortic balloon pump (IABP) in patients with cardiogenic shock due to heart failure did not improve 60-day survival or facilitate transition ...